NCT00510029View on ClinicalTrials.gov

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Arrhythmia
Interventions
DRUG

GAP-134

atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO

Trial Locations (1)

19148

Philadelphia

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00510029 - Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously | Biotech Hunter | Biotech Hunter